About Mablink
Mablink is a Healthcare company based in Lyon (France) founded in 2018 by Charles Dumontet, Warren Viricel, Benoit Joseph, and Jean Guillaume Lafay, and was acquired by Lilly in October 2023. Antibody-drug conjugate technology for cancer treatment is provided. Mablink has raised $35 million across 3 funding rounds from investors including Lilly, Crédit Agricole and Elaia. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.
Company details
Mablink was established in 2018 in Lyon, France, within the biotechnology sector. Antibody-drug conjugates for oncology applications are developed using a proprietary hydrophilic linker platform. This platform incorporates a non-polymeric 2.0 kDa linker that maintains plasma stability in homogeneous ADCs, without reliance on site-specific conjugation. Targeted products include MBK-101 and MBK-102, addressing acute myeloid leukemia and multiple myeloma.
- Headquarters Lyon, France
- Founders Charles Dumontet, Warren Viricel, Benoit Joseph, Jean Guillaume Lafay
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website mablink.com
- Social LinkedIn
- Acquired by Lilly (Oct 2023)
Funding Insights of Mablink
Mablink has successfully raised a total of $35M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $30.17 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35M
- Total Rounds 3
- Last Round Series A — $30.17M
- First Round $1.72M
(Jun 2018)
- Investors Count 9
All 3 funding rounds of Mablink with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | $30.17M | Series A | – | Sofinnova Partners, Merieux Equity Partners | |
| Apr 2021 | $4.84M | Seed | – | Elaia | |
| Jun 2018 | $1.72M | Grant | – | – | – |
10 investors in total: 10 institutional.
Investors in Mablink
Mablink has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Crédit Agricole and Elaia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on early-stage investments | elaia.com | Paris, France | ||
| pertinence-invest.com | ||||
Cancer research is supported through funding and entrepreneurial guidance. | 2007 | fournier-majoie.org | Brussels, Belgium | |
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Pivate equity firm that focuses on investing in healthcare and nutrition companies | merieux-partners.com | Lyon, France | ||
UI Investissement is engaged in private equity and investment services. | ui-investissement.com | Paris, France | ||
Offers insurance, risk management, and training for health and territorial entities. | 1927 | sham.fr | Lyon, France | |
Crédit Agricole is recognized as a leading banking institution in France. | 1894 | credit-agricole.com | Montrouge, France | |
Operates a direct-to-consumer brand offering multi-category casual wear for men and women. | 2019 | simbasante.com | New York, United States | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States |
Investor details for Mablink
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mablink
17 people are tracked at Mablink (14 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Charles Dumontet | Co-Founder | Leadership |
Warren Viricel | Co-Founder | Leadership |
Benoit Joseph | Co-Founder | Leadership |
Jean Guillaume Lafay | Co-Founder | Leadership |
Stanislas Sordet | Chief Financial Officer | Leadership |
Edouard LEROY | Chief Business Officer | Leadership |
Fréderique Brune | Chief Development Officer (CDO) | Leadership |
Lenka Kyrych Sadilkova | Head of Preclinical Research and Development | Leadership |
Valérie Attuil | COO | Leadership |
Sylvain THIERRY, PhD | Head of Pharmacology (Immuno-Oncology and Targeted Therapies). | Leadership |
Pejvack Motlagh | Chief Medical Officer | Leadership |
Delphine BREGEON, PhD, PMP | Director, Head of CMC Operations & Clinical Supply | Leadership |
Carmela Dantas-Barbosa | Director of Translational Research | Leadership |
David Doreau | Chief Quality Officer | Leadership |
Pierrick Bruyat | Research Scientist in Medicinal Chemistry | Team |
Maud Troupinon | Scientist | Team |
Aurélie Martinoni | FP&A Manager | Team |
Complete people profiles for Mablink
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Mablink
4 dated milestones of Mablink across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Mablink is founded.
- Funding First funding round of $1.7M.
- Funding Latest funding round, Series A, of $30.2M.
- Exit Acquired by Lilly.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mablink
Complete news archive for Mablink
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mablink
Mablink was founded in 2018.
Mablink is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Mablink is a funded company, having raised a total of $35M across 3 funding rounds to date. The company's 1st funding round was a Grant of $1.72M, raised on Jun 2018.
Mablink was established in 2018 in Lyon, France, within the biotechnology sector. Antibody-drug conjugates for oncology applications are developed using a proprietary hydrophilic linker platform. This platform incorporates a non-polymeric 2.0 kDa linker that maintains plasma stability in homogeneous ADCs, without reliance on site-specific conjugation. Targeted products include MBK-101 and MBK-102, addressing acute myeloid leukemia and multiple myeloma.
Mablink has 10 investors. Key investors include Lilly, Crédit Agricole, Elaia, Pertinence Invest, and Foundation Fournier-Majoie.
Yes. Mablink was acquired by Lilly in October 2023.